Hisun Pharmaceutical (002653.SZ) has revealed that it has entered into an exclusive license pact with AirNexis Therapeutics, Inc., a U.S.-based company. This agreement bestows upon AirNexis the sole and exclusive rights to develop, manufacture, and market HSK39004 on a worldwide basis, with the exception of Mainland China, Hong Kong, Macau, and Taiwan.

As per the terms of the agreement, AirNexis is obligated to make an initial payment totaling $108 million. This payment is a combination of $40 million in cash and equity shares valued at roughly $68 million. Furthermore, AirNexis may be liable to pay additional milestone payments and royalties, which could amount to up to $955 million in total.

It's important to note that this transaction qualifies as a related-party transaction. As such, it still necessitates the approval of the shareholders' meeting before it can be fully executed.